|
| Study | Year | Identifier | Site/principal investigator | Intervention | Status/enrollment |
|
| “Treatment of Patients with Newly Onset of Type 1 Diabetes with Mesenchymal Stem Cells Phase I/II” | 2010 | NCT01068951 | Uppsala University Hospital | Autologous transplantation of the patients’ own mesenchymal stem cells (approximately 2 × 106 cells/kg body weight) intravenously | Completed 2013; 20 patients |
|
| “PROCHYMAL (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM) Phase I” | 2008 | NCT00690066 | Mesoblast International Sàrl | Intravenous infusion of ex vivo cultured adult human mesenchymal stem cells (PROCHYMAL) | Completed 2011; 63 patients |
|
| “Umbilical Mesenchymal Stem Cells and Mononuclear Cells Infusion in Type 1 Diabetes Mellitus Phase I/II” | 2011 | NCT01374854 | Fuzhou General Hospital | Infusion of 1 × 106/kg UCMSCs through pancreatic artery along with mononuclear cells by interventional therapy and another administration of same dose of UCMSCs one week after intervention | Active, not recruiting; 44 patients |
|
| “Autologous Transplantation of Mesenchymal Stem Cells for Treatment of Patients with Onset of Type 1 Diabetes Phase II/III” | 2010 | NCT01157403 | Lu Debin, Third Military Medical University | Autologous transplantation of bone marrow mesenchymal stem cells (approximately 2.5 × 106 cells/kg body weight) intravenously | Recruiting; 80 patients |
|
| “Safety and Efficacy of Mesenchymal Stem Cells in Newly Diagnosed Type 1 Diabetic Patients Phase I/II” | 2010 | NCT01322789 | University of Sao Paulo | Intravenous mesenchymal stem cell infusion; four consecutive intravenous infusions 1 week apart followed by 4 consecutive infusions 1 month apart | Recruiting; 10 patients |
|
| “Cotransplantation of Islet and Mesenchymal Stem Cell in Type 1 Diabetic Patients Phase I/II” | 2008 | NCT00646724 | Fuzhou General Hospital | Cotransplantation of islet and mesenchymal stem cell; islet of allograft and MSCs of autograft | Recruiting; 30 patients |
|
| “Human Menstrual Blood-Derived Mesenchymal Stem Cells Transplantation in Treating Type 1 Diabetic Patients Phase I/II” | 2011 | NCT01496339 | S-Evans Biosciences Co., Ltd. | 1 × 106/kg MenSCs are infused through pancreatic artery or intravenous infusion once a week by the 4 consecutive therapies | Recruiting; 50 patients |
|
| “Stem Cell Therapy for Type 1 Diabetes Mellitus Phase I/II” | 2010 | NCT01143168 | Cellonis Biotechnology Co. | First transplantation: on day 0, ABM-MNCs + UCMSCs through pancreas artery; second transplantation: on day 7 ± 1, ABM-MNCs + UCMSCs intravenously; third transplantation: on day 14 ± 2, ABM-MNCs + UCMSCs intravenously | Active, not recruiting; 24 patients |
|
| “Mesenchymal Stem Cells to Intervene in the Development of Type 1 Diabetes: A Blinded Randomized Study Phase II” | 2014 | NCT02057211 | Uppsala University Hospital | Autologous mesenchymal stem cell transplantation | Recruiting; 50 patients |
|
